Skip Navigation
Skip to contents

ICDM 2018

Corporate symposia

Satellite symposium 1 Sponsored by Yuhan 17:30~18:00 / Thursday 11 October
Convention hall B
Chairman: TBD
Sang Soo Kim
Pusan National University, Korea
TBD
SS1 Why should we consider SGLT-2i treatment for T2D patients?
Satellite symposium 2Sponsored by Chongkundang Thursday 11 October 17:30~18:00 / 222
Convention hall C
Chairman: TBD
Sin Gon Kim
Korea University, Korea
Sin Gon Kim
SS2 What should be considered in choosing diabetic drug? : focused on synergistic effect of TZD and SGLTI
Satellite symposium 3Sponsored by Takeda 15:20~16:00 / Friday 12 October
Convention hall A
Chairman: TBD
Eun Jung Rhee
Sungkyunkwan University, Korea
TBD
SS3 Targeting ß-cell function in T2D: a critical factor for durability
Satellite symposium 4Sponsored by Novonordisk 15:20~16:00 / Friday 12 October
Convention hall B
Chairman: TBD
Hendrik Jarlov
Novonordisk, Denmar
TBD
SS4 Exploring the mechanisms behind better PPG control with faster aspart
Satellite symposium 5Sponsored by Lilly 15:20~16:00 / Friday 12 October
Convention hall C
Chairman: TBD
Paolo Pozzilli
University Campus Bio-Medico, Italy
TBD
SS5 TBD
Breakfast symposium 1Sponsored by MSD 08:00~09:00 / Friday 12 October
Grand Ballroom A
Chairman: TBD
Seung Hwan Lee
The Catholic University of Korea, Korea
BS1
BS1 Optimized treatment for type 2 DM patients-focusing new SGLT2i, ertugliflozin
Breakfast symposium 2Sponsored by Novartis 08:00~09:00 / Friday 12 October
Grand Ballroom C
Chairman: TBD
Hye Seung Jung
Seoul National University, Korea
BS2
BS2 Anti-diabetic agents with high potency and low risk of hypoglycemia: reducing glucose fluctuation
Breakfast symposium 3Sponsored by Sanofi Aventis 08:00~09:00 / Saturday 13 October
Grand Ballroom A
Chairman: TBD
Robert A Ritzel
Munich Schwabing Hospital, Germany
BS3
BS3 New insulin glargin-300: applying evidence to clinical practice
Breakfast symposium 4Sponsored by JW Pharmaceutical 08:00~09:00 / Saturday 13 October
Grand Ballroom C
Chairman: TBD
Jeong Hyun Park
Inje University, Korea
Jeong Hyun Park
BS4 Take a suitable treatment for type 2 DM patients
Luncheon symposium 1Sponsored by Astrazeneca 12:10~13:20 / Friday 12 October
Convention hall A
Chairman: TBD
Ofri Mosenzon
Hadassah Hebrew University, Israel
TBD
LS1 DECLARE-TIMI 58: participants' baseline characteristics
Luncheon symposium 2Sponsored by Dong-A ST 12:10~13:20 / Friday 12 October
Convention hall B
Chairman: TBD
TBD
TBD
LS2 TBD
Luncheon symposium 3Sponsored by Ildong 12:10~13:20 / Friday 12 October
Convention hall C
Chairman: TBD
Suk Chon
Kyung Hee University, Korea
TBD
LS3 DPP4 inhibitor : beta cell protection and albuminuria improvement effect found from evidence
Luncheon symposium 4Sponsored by Daewoong 12:10~13:20 / Friday 12 October
Emerald hall A
Chairman: TBD
TBD
TBD
LS4 TBD
Luncheon symposium 5Sponsored by LG 12:20~13:30 / Saturday 13 October
Convention hall A
Chairman: TBD
So Hun Kim
Inha University, Korea
TBD
LS5 TBD
Luncheon symposium 6Sponsored by Handok 12:20~13:30 / Saturday 13 October
Convention hall B
Chairman: TBD
Jun Sung Moon
Yeungnam University, Korea
TBD
LS6 The multiple benefits of ipragliflozin; ideal option for Asian T2DM patients
Luncheon symposium 7Sponsored by Boehringer Ingelheim 12:20~13:30 / Saturday 13 October
Convention hall C
Chairman: TBD
Mark E Cooper
Monash University, Australia
Mark Cooper
LS7 TBD